{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:04:22Z","timestamp":1790834662546,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1136\/ard.2002.003889","type":"journal-article","created":{"date-parts":[[2003,11,23]],"date-time":"2003-11-23T00:05:33Z","timestamp":1069545933000},"page":"1204-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study"],"prefix":"10.1016","volume":"62","author":[{"given":"N","family":"Tsifetaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kitsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Paschides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Alamanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Eftaxias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P V","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Psilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2002.003889_bib1","doi-asserted-by":"crossref","unstructured":"Talal N, Moutsopoulos HM, Kassan SS., eds. Sj\u00f6gren\u2019s syndrome: clinical and immunological aspects. Berlin: Springer, 1987.","DOI":"10.1007\/978-3-642-50118-0"},{"key":"10.1136\/ard.2002.003889_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sj\u00f6gren\u2019s syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard.2002.003889_bib3","first-page":"2051","article-title":"Sj\u00f6gren\u2019s syndrome: a critical review of clinical management","volume":"26","author":"Bell","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2002.003889_bib4","unstructured":"Fox R. Treatment of Sj\u00f6gren\u2019s syndrome. In: Weinblatt ME, ed. Therapy of rheumatoid disease. Philadelphia: Saunders, 1999:66\u201377."},{"key":"10.1136\/ard.2002.003889_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0002-9394(00)00620-6","article-title":"Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome","volume":"131","author":"Balaram","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.2002.003889_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003495-199549010-00010","article-title":"Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia","volume":"49","author":"Wiseman","year":"1995","journal-title":"Drugs"},{"key":"10.1136\/ard.2002.003889_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2002.003889_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2303.1993.tb00113.x","article-title":"Impression cytology in patients with keratoconjunctivitis sicca","volume":"4","author":"de Rojas","year":"1993","journal-title":"Cytopathology"},{"key":"10.1136\/ard.2002.003889_bib9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P","article-title":"Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotrasmission in Sjogren\u2019s syndrome","volume":"43","author":"Waterman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2002.003889_bib10","first-page":"3","article-title":"Sj\u00f6gren\u2019s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems","volume":"116","author":"Fox","year":"2002","journal-title":"Scand J Rheumatol Supple"},{"key":"10.1136\/ard.2002.003889_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0002-9343(88)90365-8","article-title":"Treatment for primary Sj\u00f6gren\u2019s syndrome with hydroxychloroquine","volume":"85","author":"Fox","year":"1988","journal-title":"Am J Med"},{"key":"10.1136\/ard.2002.003889_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin A (CyA) in primary Sj\u00f6gren\u2019s syndrome: a double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2002.003889_bib13","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren\u2019s syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2002.003889_bib14","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2002.003889_bib15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratocojunctivitis","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2002.003889_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1136\/ard.2002.003889_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group","volume":"19","author":"Ship","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard.2002.003889_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00002281-200009000-00007","article-title":"Update in Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Fox","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2002.003889_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(97)01338-1","article-title":"Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs","volume":"339","author":"Masunaga","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1136\/ard.2002.003889_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren\u2019s syndrome: a randomized placebo-controlled, fixed-dose, multicenter trial. P92\u201301 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2002.003889_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0030-4220(92)90066-Y","article-title":"Effects of pilocarpine on salivary flow in patients with Sj\u00f6gren\u2019s syndrome","volume":"74","author":"Fox","year":"1992","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1136\/ard.2002.003889_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1601-0825.1997.tb00019.x","article-title":"Oral pilocarpine HC1 stimulates labial (minor) salivary gland flow in patients with Sj\u00f6gren\u2019s syndrome","volume":"3","author":"Rhodus","year":"1997","journal-title":"Oral Dis"},{"issue":"suppl 115","key":"10.1136\/ard.2002.003889_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/030097401300232583","article-title":"The treatment of Sj\u00f6gren\u2019s syndrome patients with pilocarpine tablets","volume":"30","author":"Vivino","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.2002.003889_bib24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind randomized, placebo-controlled study of cevimeline in Sj\u00f6gren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2002.003889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T08:27:36Z","timestamp":1736065656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724087065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0003496724087065"],"URL":"https:\/\/doi.org\/10.1136\/ard.2002.003889","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2002.003889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Copyright 2003 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}